Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05539430 | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma | PHASE1 | ACTIVE NOT_RECRUITING | 56 | — | — | Apr 18, 2023 | Dec 1, 2027 | Dec 12, 2025 | 9 | United States |
Multiple doses will be tested to establish a recommended dose.
Treatment of additional patients at the recommended dose as identified in the initial dose escalation part of the study.
| Arm | Type | Description |
|---|---|---|
| Experimental LB1908 | EXPERIMENTAL | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells |
| Name | Type | Description |
|---|---|---|
| LB1908 | BIOLOGICAL | Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells |
Inclusion Criteria: For inclusion in the study, all of the following inclusion criteria must be fulfilled. 1. Be willing and able to provide written informed consent. 2. Be a female or male ≥ 18 and ≤ 75 years old at the time of signing of the prescreening ICF. 3. For Part A and Part B Cohort MR1 ...